Zhejiang Jingsheng Pharmaceutical is an API manufacturer based in China. It holds 11 active US drug master files and 3 valid CEPs across a filed portfolio of 10 molecules.
| Site | FDA FEI |
|---|---|
| Taizhou, China | Not on file |
| Taizhou City, China | Not on file |
| China, China | 3017488372 |
| Molecule | Regulators | Docs |
|---|---|---|
| Sitagliptin | EDQM, US FDA | 4 |
| Dapagliflozin | US FDA | 2 |
| Empagliflozin | US FDA | 1 |
| Enzalutamide | US FDA | 1 |
| Ezetimibe | US FDA | 1 |
| Finerenone | US FDA | 1 |
| Losartan Potassium | EDQM | 1 |
| Mirogabalin | US FDA | 1 |
| Telmisartan | US FDA | 1 |
| Vonoprazan | US FDA | 1 |
Also appears on these molecule pages
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Ask Fred what the record holds on Zhejiang Jingsheng Pharmaceutical, including filings and inspection history.
Chat with Fred, your AI analystRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.